MX2020010121A - Compuestos con actividad antitumoral contra celulas de cancer que portan las mutaciones del exon 19 del receptor 2 del factor de crecimiento epidermico humano. - Google Patents
Compuestos con actividad antitumoral contra celulas de cancer que portan las mutaciones del exon 19 del receptor 2 del factor de crecimiento epidermico humano.Info
- Publication number
- MX2020010121A MX2020010121A MX2020010121A MX2020010121A MX2020010121A MX 2020010121 A MX2020010121 A MX 2020010121A MX 2020010121 A MX2020010121 A MX 2020010121A MX 2020010121 A MX2020010121 A MX 2020010121A MX 2020010121 A MX2020010121 A MX 2020010121A
- Authority
- MX
- Mexico
- Prior art keywords
- exon
- compounds
- growth factor
- cancer cells
- activity against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648629P | 2018-03-27 | 2018-03-27 | |
| US201862688049P | 2018-06-21 | 2018-06-21 | |
| PCT/US2019/024353 WO2019191279A2 (en) | 2018-03-27 | 2019-03-27 | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010121A true MX2020010121A (es) | 2021-01-08 |
Family
ID=68060750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010121A MX2020010121A (es) | 2018-03-27 | 2019-03-27 | Compuestos con actividad antitumoral contra celulas de cancer que portan las mutaciones del exon 19 del receptor 2 del factor de crecimiento epidermico humano. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210361655A1 (enExample) |
| EP (1) | EP3773551B1 (enExample) |
| JP (1) | JP7386174B2 (enExample) |
| KR (1) | KR102899689B1 (enExample) |
| CN (1) | CN112088000A (enExample) |
| AU (1) | AU2019243738B2 (enExample) |
| BR (1) | BR112020019251A2 (enExample) |
| CA (1) | CA3094108A1 (enExample) |
| IL (1) | IL277373A (enExample) |
| MX (1) | MX2020010121A (enExample) |
| PH (1) | PH12020551495A1 (enExample) |
| RU (1) | RU2020134932A (enExample) |
| SG (1) | SG11202009498RA (enExample) |
| WO (1) | WO2019191279A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113271948B (zh) * | 2018-12-21 | 2024-08-16 | 得克萨斯大学体系董事会 | 治疗癌症的联合疗法 |
| AU2020254499A1 (en) * | 2019-03-29 | 2021-10-28 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 insertions |
| SG11202111120VA (en) * | 2019-04-17 | 2021-11-29 | Univ Texas | Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| JPH08506247A (ja) | 1993-07-09 | 1996-07-09 | アムジェン ボールダー インコーポレイテッド | 組換えｃｔｌａ４ポリペプチドおよびその製造方法 |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US5869245A (en) | 1996-06-05 | 1999-02-09 | Fox Chase Cancer Center | Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands |
| US5844905A (en) | 1996-07-09 | 1998-12-01 | International Business Machines Corporation | Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| US6723564B2 (en) | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
| HRP20130077A2 (hr) | 1998-12-23 | 2013-07-31 | Pfizer Inc. | Humana monoklonalna protutjela za ctla-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| US7935500B2 (en) | 2002-03-26 | 2011-05-03 | Massachusetts Institute Of Technology | Identifying calcineurin activators for treatment of schizophrenia |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| PL3053932T3 (pl) | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| KR101217526B1 (ko) | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
| US8828391B2 (en) * | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| KR101317809B1 (ko) * | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| RU2016107426A (ru) | 2013-08-02 | 2017-09-07 | Адуро Байотек Холдингс, Юроуп Б.В. | Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета |
| US20180057603A1 (en) * | 2013-08-09 | 2018-03-01 | The Trustees Of The University Of Pennsylvania | Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| JP6782698B2 (ja) * | 2014-12-12 | 2020-11-11 | セルキュイティー インコーポレイテッド | がん患者を診断および処置するためのｅｒｂｂシグナル伝達経路活性の測定方法 |
| JP2018504418A (ja) * | 2015-02-05 | 2018-02-15 | ティルノーヴォ リミテッド | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
| MA46852A (fr) * | 2016-11-17 | 2019-09-25 | Univ Texas | Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20 |
| KR20190054826A (ko) * | 2017-11-14 | 2019-05-22 | 한미약품 주식회사 | 암의 포지오티닙 치료에 대한 반응을 나타내는 바이오마커 및 그의 용도 |
| CN113271948B (zh) * | 2018-12-21 | 2024-08-16 | 得克萨斯大学体系董事会 | 治疗癌症的联合疗法 |
| WO2020136417A2 (en) * | 2018-12-27 | 2020-07-02 | Pratik Sharma | Manoeuvring subsystem of unmanned aerial vehicle |
-
2019
- 2019-03-27 CA CA3094108A patent/CA3094108A1/en active Pending
- 2019-03-27 CN CN201980022143.3A patent/CN112088000A/zh active Pending
- 2019-03-27 BR BR112020019251-1A patent/BR112020019251A2/pt not_active IP Right Cessation
- 2019-03-27 SG SG11202009498RA patent/SG11202009498RA/en unknown
- 2019-03-27 EP EP19775368.4A patent/EP3773551B1/en active Active
- 2019-03-27 JP JP2020551912A patent/JP7386174B2/ja active Active
- 2019-03-27 AU AU2019243738A patent/AU2019243738B2/en not_active Expired - Fee Related
- 2019-03-27 US US17/042,012 patent/US20210361655A1/en active Pending
- 2019-03-27 MX MX2020010121A patent/MX2020010121A/es unknown
- 2019-03-27 RU RU2020134932A patent/RU2020134932A/ru unknown
- 2019-03-27 WO PCT/US2019/024353 patent/WO2019191279A2/en not_active Ceased
- 2019-03-27 KR KR1020207029032A patent/KR102899689B1/ko active Active
-
2020
- 2020-09-15 IL IL277373A patent/IL277373A/en unknown
- 2020-09-17 PH PH12020551495A patent/PH12020551495A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112088000A (zh) | 2020-12-15 |
| RU2020134932A (ru) | 2022-04-27 |
| US20210361655A1 (en) | 2021-11-25 |
| KR102899689B1 (ko) | 2025-12-12 |
| EP3773551B1 (en) | 2024-10-16 |
| AU2019243738A1 (en) | 2020-10-08 |
| WO2019191279A3 (en) | 2019-11-07 |
| AU2019243738B2 (en) | 2024-05-30 |
| KR20200136417A (ko) | 2020-12-07 |
| WO2019191279A2 (en) | 2019-10-03 |
| CA3094108A1 (en) | 2019-10-03 |
| IL277373A (en) | 2020-11-30 |
| PH12020551495A1 (en) | 2021-09-01 |
| JP7386174B2 (ja) | 2023-11-24 |
| JP2021519306A (ja) | 2021-08-10 |
| EP3773551A2 (en) | 2021-02-17 |
| BR112020019251A2 (pt) | 2021-01-12 |
| SG11202009498RA (en) | 2020-10-29 |
| EP3773551A4 (en) | 2022-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191303A1 (es) | Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2 | |
| MX420412B (es) | Plinabulina, composiciones que la comprenden y sus usos en el tratamiento de cáncer asociado con mutación del egfr. | |
| JOP20250258A1 (ar) | مثبطات 2-آزا باي سيكلو هبتان kras | |
| MX2021013218A (es) | Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2. | |
| MX389700B (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| PH12021552579A1 (en) | Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations | |
| MX2020009773A (es) | Terapia de combinacion. | |
| PH12021552395A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions | |
| PH12020552135A1 (en) | Kdm1a inhibitors for the treatment of disease | |
| NI201500123A (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
| MD20160016A2 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| CY1118073T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης | |
| MX2020008395A (es) | Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas. | |
| MX2021012335A (es) | Anticuerpos humanos que se unen a ret y metodos de uso de los mismos. | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| PH12020551495A1 (en) | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations | |
| MX380758B (es) | Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo. | |
| BR112018011196A2 (pt) | uso de pirimido-pirimidazinonas para tratar o câncer | |
| PH12021552110A1 (en) | Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions | |
| PH12021551276A1 (en) | Combination therapy for the treatment of cancer |